GenMark Diagnostics will price $60 million public offering of shares

Bookrunner J.P. Morgan assists; deal funds general corporate purposes

By Devika Patel

Knoxville, Tenn., Aug. 12 - GenMark Diagnostics, Inc. plans to conduct a $60 million public sale of common shares, according to a preliminary prospectus supplement filed Monday with the Securities and Exchange Commission. The deal is expected to have a $9 million greenshoe.

J.P. Morgan is the bookrunning manager.

Proceeds will be used for general corporate purposes, including acceleration of the company's test menu and NexGen platform development, expansion, automation of manufacturing infrastructure and other working capital requirements.

The molecular diagnostics company is based in Pasadena, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.